Samsung Biologics hits revenue high, secures largest contract to date

Anna Brown

News Reporter

Samsung Biologics closed 2024 on several high notes, reaching its highest annual revenue to date — and just a week ago, securing its largest client contract …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Samsung Biologics hits revenue high, secures largest contract to date

Anna Brown

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Updated: Biogen makes cuts across its research unit, shifting focus to ‘external opportunities’

Chinese startup begins first trial of in vivo CRISPR therapy for blood disease

RFK Jr. says he’ll divest interests in CRISPR Therapeutics if confirmed for HHS chief

'No miracles': What Regeneron's George Yancopoulos really thinks of AI

GLP-1s can cut the risk of Alzheimer’s. What does that mean for Novo Nordisk?

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

Sam­sung Bi­o­log­ics hits rev­enue high, se­cures largest con­tract to date

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Samsung Biologics hits revenue high, secures largest contract to date